Eli Lilly and Company (NYSE:LLY) Stock Price Down 2.2% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s share price traded down 2.2% during mid-day trading on Thursday . The company traded as low as $973.16 and last traded at $977.4720. 2,326,214 shares were traded during mid-day trading, a decline of 28% from the average session volume of 3,211,158 shares. The stock had previously closed at $999.84.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CMS/Medicare expansion meaningfully broadens access to Lilly’s leading tirzepatide products (Zepbound, Mounjaro), increasing the company’s addressable market and supporting revenue upside. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Large, long-term China investment: Lilly announced a multi‑billion-dollar (reported ~$3B) manufacturing/supply‑chain buildout in China to secure capacity for its next‑gen oral and injectable GLP‑1s — this reduces supply risk and targets a huge, growing market. Eli Lilly to invest $3 billion in China over next decade
• Positive Sentiment: Pipeline and product catalysts remain bullish: Lilly has filed/advanced its oral GLP‑1 (orforglipron) and reported favorable head‑to‑head data vs. competitors, supporting near‑term launches and long‑term growth. This underpins analyst upside and premium valuation. Eli Lilly Widens Access to Weight-Loss Injectable as Lower-Cost Pill Nears Approval
• Positive Sentiment: Strategic ecosystem investments (Korea Gateway Labs / $500M pledge, Samsung Biologics partnership) expand R&D/partner capacity and local market presence, which can accelerate future product commercialization. Eli Lilly Taps Samsung Biologics To Grow Korean Biotech And Long Term Value
• Neutral Sentiment: Market-structure/speculation items (stock-split chatter and “GLP‑1 pill wars” coverage) keep retail interest high but are more sentiment/flow-driven than fundamental catalysts. These can amplify moves but don’t change the fundamentals immediately.
• Negative Sentiment: Lilly issued a public warning about an unknown impurity found in compounded tirzepatide mixed with vitamin B12 — safety concerns and negative headlines can pressure prescribing, invite regulatory scrutiny of compounding practices, and spur short‑term volatility. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Sentiment/technical concerns: some analysts/commentators note fading trading momentum and “peak euphoria” for GLP‑1 names after a huge run, which can trigger profit‑taking in a richly valued stock. Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November
• Negative Sentiment: Regulatory/market constraints in key geographies — e.g., India warning against weight‑loss drug advertising — could limit marketing channels and slow uptake in large markets. India warns drugmakers against direct or surrogate weight-loss drug obesity ads

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. HSBC reaffirmed a “hold” rating and set a $1,070.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Rothschild & Co Redburn increased their price objective on Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a report on Monday, January 26th. Finally, TD Cowen boosted their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,229.59.

Eli Lilly and Company Trading Down 2.2%

The stock’s fifty day moving average price is $1,041.12 and its 200 day moving average price is $947.08. The stock has a market cap of $923.54 billion, a P/E ratio of 42.59, a PEG ratio of 1.16 and a beta of 0.40. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter in the prior year, the business posted $5.32 EPS. The firm’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $25,000. Sumitomo Mitsui Financial Group Inc. purchased a new position in shares of Eli Lilly and Company in the second quarter worth approximately $27,000. Vermillion & White Wealth Management Group LLC grew its position in Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares during the period. Evolution Wealth Management Inc. bought a new stake in Eli Lilly and Company during the second quarter valued at approximately $29,000. Finally, Steph & Co. increased its holdings in Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.